Serum interleukin-6 level and its association with pulmonary involvement in progressive systemic sclerosis; a case-control study.
EUSTAR score
Interleukin-6
Pulmonary Involvement
Systemic sclerosis
Journal
Clinical and molecular allergy : CMA
ISSN: 1476-7961
Titre abrégé: Clin Mol Allergy
Pays: England
ID NLM: 101152195
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
26
06
2022
accepted:
26
07
2023
medline:
6
9
2023
pubmed:
6
9
2023
entrez:
5
9
2023
Statut:
epublish
Résumé
Primary Systemic Sclerosis (PSS) is a connective tissue disorder characterized by excessive collagen deposition in the skin and internal organs. Interstitial lung disease (ILD) is a late demonstration of PSS and cytokines can contribute to the disease pathology. The purpose of the current study was to determine the association between serum interleukin-6 level and pulmonary involvement in progressive systemic sclerosis. Demographic data and serum interleukin-6 levels were measured for 30 PSS patients with pulmonary involvement (case group) and 30 PSS patients without pulmonary involvement (control group) following informed consent. The disease duration and activity, C-reactive protein (CRP), chest x-ray and highresolution CT scan (HRCT) findings, ejection fraction (EF) and echocardiography findings, and pulmonary artery pressure (PAP) were also determined in both groups. The age of patients in case and control groups was 52.5 ± 9.3 and 43.9 ± 9.7 years, respectively (p = 0.001). No significant difference was found between serum levels of IL-6 in case and control groups (73.1 ± 95.4 vs 46.7 ± 83.6 pg/ml, p = 0.267). However, IL-6 level was significantly higher in male case patients compared to male controls (p = 0.007). The duration of PSS was 11.6 ± 6.4 and 7.4 ± 4.2 years in case and control groups, respectively (p = 0.002). The quantitative CRP and PAP was also significantly higher in case patients (p = 0.01 and p < 0.001, respectively). There was found reticulonodular pattern in 20 (66.7%) of the cases, whereas 28 (93.3%) of the controls had normal Chest X-rays (CXR) (p < 0.001). EF was significantly lower in case patients compared to control patients (p = 0.001). The serum level of IL-6 did not appear to have a relationship with pulmonary involvement, hence it could not be regarded as a potential therapeutic target.
Sections du résumé
BACKGROUND
BACKGROUND
Primary Systemic Sclerosis (PSS) is a connective tissue disorder characterized by excessive collagen deposition in the skin and internal organs. Interstitial lung disease (ILD) is a late demonstration of PSS and cytokines can contribute to the disease pathology. The purpose of the current study was to determine the association between serum interleukin-6 level and pulmonary involvement in progressive systemic sclerosis.
METHODS AND MATERIALS
METHODS
Demographic data and serum interleukin-6 levels were measured for 30 PSS patients with pulmonary involvement (case group) and 30 PSS patients without pulmonary involvement (control group) following informed consent. The disease duration and activity, C-reactive protein (CRP), chest x-ray and highresolution CT scan (HRCT) findings, ejection fraction (EF) and echocardiography findings, and pulmonary artery pressure (PAP) were also determined in both groups.
RESULTS
RESULTS
The age of patients in case and control groups was 52.5 ± 9.3 and 43.9 ± 9.7 years, respectively (p = 0.001). No significant difference was found between serum levels of IL-6 in case and control groups (73.1 ± 95.4 vs 46.7 ± 83.6 pg/ml, p = 0.267). However, IL-6 level was significantly higher in male case patients compared to male controls (p = 0.007). The duration of PSS was 11.6 ± 6.4 and 7.4 ± 4.2 years in case and control groups, respectively (p = 0.002). The quantitative CRP and PAP was also significantly higher in case patients (p = 0.01 and p < 0.001, respectively). There was found reticulonodular pattern in 20 (66.7%) of the cases, whereas 28 (93.3%) of the controls had normal Chest X-rays (CXR) (p < 0.001). EF was significantly lower in case patients compared to control patients (p = 0.001).
CONCLUSION
CONCLUSIONS
The serum level of IL-6 did not appear to have a relationship with pulmonary involvement, hence it could not be regarded as a potential therapeutic target.
Identifiants
pubmed: 37670355
doi: 10.1186/s12948-023-00188-1
pii: 10.1186/s12948-023-00188-1
pmc: PMC10478355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Informations de copyright
© 2023. Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and BioMed Central Ltd., part of Springer Nature.
Références
Am J Respir Crit Care Med. 1994 May;149(5):1260-5
pubmed: 8173768
Int J Rheumatol. 2011;2011:721608
pubmed: 21941555
J Rheumatol. 2013 Apr;40(4):435-46
pubmed: 23378460
Arthritis Res Ther. 2009;11(4):R111
pubmed: 19615053
Front Cell Infect Microbiol. 2017 Jun 30;7:290
pubmed: 28713777
Iran J Reprod Med. 2013 Jan;11(1):65-70
pubmed: 24639695
Ann Rheum Dis. 2011 Feb;70(2):366-72
pubmed: 21068092
J Dermatol. 1996 Oct;23(10):677-82
pubmed: 8973032
J Gastrointest Oncol. 2019 Jun;10(3):537-545
pubmed: 31183205
Probiotics Antimicrob Proteins. 2016 Mar;8(1):41-5
pubmed: 26920557
J Dermatol Sci. 2001 Oct;27(2):140-6
pubmed: 11532378
Science. 2007 Jul 6;317(5834):121-4
pubmed: 17615358
Asian Pac J Cancer Prev. ;18(2):523-527
pubmed: 28345840
Probiotics Antimicrob Proteins. 2016 Dec;8(4):211-214
pubmed: 27530282
Osong Public Health Res Perspect. 2016 Aug;7(4):273-7
pubmed: 27635378
Cell J. 2013 Spring;15(1):11-8
pubmed: 23700556
J Clin Invest. 2007 Mar;117(3):557-67
pubmed: 17332883
Radiology. 1990 Sep;176(3):755-9
pubmed: 2389033
Glob J Health Sci. 2015 Jun 25;8(2):185-9
pubmed: 26383191
Rheumatology (Oxford). 2013 Jul;52(7):1298-302
pubmed: 23538743
Autoimmun Rev. 2015 Jul;14(7):575-8
pubmed: 25709096
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Clin Exp Immunol. 2004 Dec;138(3):540-6
pubmed: 15544634
Glob J Health Sci. 2015 May 29;8(1):249-54
pubmed: 26234967
J Chronic Dis. 1966 Sep;19(9):953-77
pubmed: 5966290